logo-loader

Full interview: Pressure BioSciences CEO sees potential opportunity to enter clinical market after recent customer data

Published: 08:29 11 Sep 2019 EDT

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical market space.

The two separate cancer research organizations, who are some of Pressure's largest customers, published findings that showcased PCT’s ability to discover biomarkers associated with cancer in tissue samples preserved from biopsies and highlighted its potential as a diagnostic tool.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 35 minutes ago